TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Net Income
Bottom-line profit, the starting point for calculating cash from operations.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $1.54M, compared with -$10.38M a year earlier. Trailing-twelve-month net income was -$27.31M. Over 3 fiscal years it compounded at -6.0% a year.
Context
- Net income amounted to 86.9% of revenue in FY2025, down 15.2 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$16.56M (-57.8%) for the fiscal year ending Dec 2026, a slowdown from the +30.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.54M+115.8% QoQ
- Last fiscal yearDec 2025
- -$39.23M+30.6% YoY
- LTMMar 2026
- -$27.31M+0.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +114.8% | +9.4% | -105.5 pp |
| 1 year | +30.6% | -57.8% | -88.3 pp |
| 3-year CAGR | -6.0% | -41.2% | -35.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (39.23M) USD
- Year-over-year change
- -30.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.23M) | -30.6% |
| FY2024 | 2024-12-31 | (30.05M) | +49.4% |
| FY2023 | 2023-12-31 | (59.36M) | -25.8% |
| FY2022 | 2022-12-31 | (47.19M) | -63.6% |
| FY2021 | 2021-12-31 | (28.85M) | — |
Net Income vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's LTM Mar 2026 net income of $27.31M is the 10th largest of the 11 companies compared; the peer median is $55.72M.
- Its year-over-year change of +0.4% is the 9th highest of 11, against a peer median of +33.2%.
- Net income amounts to 60.9% of revenue for TLSI, versus a peer median of 164.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $282.61M | +66241.3% | +67.6% | 9554.2% | |
| LTM Mar 2026 | $111.13M | +30.5% | +91.6% | 17982.7% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $88.03M | +7.6% | +45.5% | 4756.0% |
| LTM Dec 2025 | $75.02M | +40.2% | -10.7% | 576.1% | |
| LTM Mar 2026 | $65.41M | +35.9% | -34.8% | 57.5% | |
| LTM Mar 2026 | $46.04M | +260.1% | -21.4% | 43.0% | |
| LTM Mar 2026 | $39.2M | +21.2% | +14.1% | 207.7% | |
| LTM Mar 2026 | $39.12M | -6.4% | +23.7% | 121.2% | |
| LTM Mar 2026 | $37.52M | -22.7% | +1.7% | 24.7% | |
| LTM Mar 2026 | $27.31M | +0.4% | -6.0% | 60.9% | |
| LTM Mar 2026 | $11.98M | +121.2% | +19.8% | 20.8% | |
| Peer median (excluding TLSI) | $55.72M | +33.2% | +17.0% | 164.4% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.85M) | (47.19M) | (59.36M) | (30.05M) | (39.23M) |
| Depreciation & Amortization | 464K | 398K | 684K | 744K | 626K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 109K | 368K | 1.4M | 5.44M | 9.13M |
| Change in Working Capital | (131K) | 2.3M | 537K | (9.55M) | 2.07M |
| Accounts Receivables | (741K) | (200K) | (1.98M) | (1.72M) | (1.63M) |
| Inventory | (725K) | (179K) | (1.07M) | (1.5M) | 971K |
| Accounts Payables | 3.18M | 5.25M | 2.84M | (4.38M) | 2.02M |
| Other Working Capital | (1.84M) | (2.57M) | 751K | (1.94M) | 711K |
| Other Non-Cash Items | 5.71M | 11.81M | 6.16M | (7.43M) | 9.39M |
| Operating Cash Flow | (22.7M) | (32.31M) | (50.58M) | (40.84M) | (18.01M) |
| Capital Expenditures | (1.26M) | (786K) | (588K) | (345K) | (918K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 80K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1.16M) | (1.13M) | (1M) | 0 | 0 |
| Investing Cash Flow | (2.26M) | (1.79M) | (1.59M) | (345K) | (838K) |
| Debt Repayment | (1.3M) | (131K) | (87K) | 24.92M | 9.92M |
| Common Stock Issued | 0 | 0 | 0 | 15.54M | 22.91M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54K | 94K | 45.53M | (2.52M) | (2.07M) |
| Financing Cash Flow | 50.77M | 13.46M | 54.63M | 37.94M | 30.76M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.81M | (20.64M) | 2.46M | (3.25M) | 11.91M |
| Free Cash Flow | (23.96M) | (33.1M) | (51.17M) | (41.19M) | (18.93M) |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.